ArticleEuropean journal of medical research2025
Apolipoprotein A-I: a non-negligible marker in hypertriglyceridemia-induced acute pancreatitis.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHypertriglyceridemia-induced acute pancreatitis (HTG-AP) is a severe subtype of pancreatitis with rapid progression and high mortality. Apolipoprotein A-I (ApoA-I), a key component of high-density lipoprotein (HDL), has anti-inflammatory and immunomodulatory properties, but its prognostic role in HTG-AP remains unclear. This study aimed to evaluate the correlation between ApoA-I levels and disease severity, progression, and clinical outcomes in HTG-AP patients.
methodsA retrospective analysis was conducted on 154 HTG-AP patients admitted to the Second Affiliated Hospital of Nanchang University. Clinical, laboratory, and imaging data were collected, including ApoA-I levels, modified computed tomography severity index (MCTSI), Ranson and Acute Physiology and Chronic Health Evaluation II (APACHE II) score, hospitalization costs, and disease severity (mild acute pancreatitis (MAP)/moderately severe acute pancreatitis (MSAP)/severe acute pancreatitis (SAP)). Statistical analyses assessed correlations between ApoA-I and these parameters.
resultsApoA-I in HTG-AP patients was significantly lower than the normal reference range (0.83 vs.1.20-1.60 g/L, p < 0.05). Lower ApoA-I correlated with higher MCTSI score (OR = 0.093, p = 0.001), Ranson score (r = - 0.36, p < 0.001), and APACHE II score (r = - 0.35, p < 0.001). Patients with severe disease (MSAP/SAP) had lower ApoA-I than MAP patients (0.755 ± 0.377 vs.1.033 ± 0.319 g/L, p = 0.001). ApoA-I also negatively correlated with hospitalization costs (r = - 0.25, p = 0.002). Receiver operating characteristic (ROC) curve analysis identified ApoA-I < 0.815 g/L as predictive of severe progression (sensitivity 80%, specificity 63.4%).
conclusionsApoA-I was a promising early biomarker for HTG-AP severity and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.